Cetuximab Rechallenge Study

Metastatic Colorectal Cancer Clinical Trial

Official title:

A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01832467
• Other study ID #: COL019
• Status: Completed
• Phase: Phase 2
• Start date: April 24, 2013
• Est. completion date: April 7, 2020

Study information

• Verified date: June 2020
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: April 7, 2020
• Est. primary completion date: April 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older.

• Able to give written informed consent.

• Histologically confirmed colorectal adenocarcinoma: must be either metastatic disease or unresectable recurrent disease.

• KRAS mutation status of the primary or metastastic CRC tumor must be wild-type.

• ECOG performance status of 0-1 at study entry.

• Must have measurable disease by RECIST (ver 1.1) criteria.

• Have progressive disease based on all of the following criteria (from a-d):

(a) Previously received cetuximab-based chemotherapy as first- or second-line treatment for metastatic or recurrent disease with, any one of the following drug combinations: (i) Cetuximab, fluoropyrimidines and oxaliplatin; or, (ii) Cetuximab, fluoropyrimidines and irinotecan; or (iii) Cetuximab and irinotecan. (b) Must have achieved at least stable disease, partial or complete response to treatment stated in '(a)' above.

(c) Experienced disease progression after more than 60 days from the last date of administration of the treatment stated in '(a)' above.

(d) 'Disease progression' can be defined as radiological or clinical progression.

• Adequate hematologic, renal, hepatic function as defined by: absolute neutrophil count >= 1.5 x 109/L, hemoglobin >= 9 g/L, platelets >= 100 x 109/L, calculated creatinine clearance >=55 ml/min, total bilirubin <= 2 x the upper limit of normal (ULN), alanine aminotransferase (ALT) <2.5 upper limit of normal or <= 5 x ULN in the presence of liver metastases.

• Must have recovered to grade 0-1 in severity, any toxicity related to previous cetuximab.

Exclusion Criteria:

• Disease progression during first-line or second-line treatment with cetuximab and chemotherapy in combination.

• Patients who had prior cetuximab in BOTH first and second-line setting.

• Previous use of bevacizumab.

• Prior grade 3 to 4 hypersensitivity reaction to cetuximab.

• Clinically significant and poorly controlled medical illnesses within the last 6 months which may be exacerbated by study treatment.

• Estimated life expectancy of less than 3 months.

• Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before enrollment. Radiotherapy for pain relief is allowed as long as not targeted at an index or non-index lesion, e.g., bone metastases.

• Known brain and/or leptomeningeal metastases.

• Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias

• Pregnancy or lactation

• Previous malignancy other than colorectal cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix. The non-CRC malignancy must be in known complete remission for at least 5 years prior to enrollment.

• The presence of KRAS mutation in any of the CRC tumor tissue(s) - for example, patients with synchronous primary CRCs with different KRAS mutation status.

• Participants with reproductive potential who are unwilling to perform effective contraception.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• cetuximab-containing chemotherapy

Locations

Country	Name	City	State
Hong Kong	Department of Clinical Oncology, Prince of Wales Hospital	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall response of re-treatment with cetuximab-based chemotherapy	in patients experiencing disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.	2 years
Secondary	Adverst event and toxicity during treatment period		2 years
Secondary	disease control rate		2 years
Secondary	progression-free survival		2 years